Effect of vanadium(IV) compounds in the treatment of diabetes: in vivo and in vitro studies with vanadyl sulfate and bis(maltolato)oxovandium(IV) - Willsky, G.R; Goldfine, A.B; Kostyniak, P.J; McNeill, J.H; Yang, L.Q; Khan, H.R; Crans, D.C (Journal of inorganic biochemistry, 2001)
Keywords: Animals; Apoproteins - chemistry; Apoproteins - metabolism; Biological Availability; Bis(maltolato)oxovandium(IV); Blood Glucose - analysis; Blood Glucose - metabolism; BMOV; Diabetes; Diabetes Mellitus, Experimental - blood; Diabetes Mellitus, Experimental - drug therapy; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; Electron Spin Resonance Spectroscopy; EPR; Fasting; Humans; Hypoglycemic Agents - chemistry; Hypoglycemic Agents - metabolism; Hypoglycemic Agents - pharmacology; Immunoglobulin G - chemistry; Immunoglobulin G - metabolism; Male; Pyrones - chemistry; Pyrones - metabolism; Pyrones - pharmacology; Rats; Rats, Wistar; Serum Albumin - chemistry; Serum Albumin - metabolism; Streptozocin; Transferrin - chemistry; Transferrin - metabolism; Treatment Outcome; Vanadates - chemistry; Vanadates - metabolism; Vanadates - pharmacology; Vanadium - blood; Vanadium - urine; Vanadium Compounds - chemistry; Vanadium Compounds - metabolism; Vanadium Compounds - pharmacology; Vanadyl sulfate; EPR; EPR, electron paramagnetic resonance; GFAAS, graphite furnace atomic absorption spectrometry; V, vanadium; STZ, streptozotocin; IgG, immunoglobulin (purified IgG fraction); BMOV; HSA, human serum albumin; Vanadyl sulfate; VOSO 4, vanadyl sulfate; i.p., intraperitoneal; VO(malto) 2 frequently seen as BMOV, bis(maltolato)oxovandium(IV); NMR, nuclear magnetic resonance; Diabetes; apoHTf, human apotransferrin; Hepes, N-[2[hydroxyethyl]piperazine- N′-[2-ethanesulfonic acid]; Bis(maltolato)oxovandium(IV)